Cargando…
Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize P...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726073/ https://www.ncbi.nlm.nih.gov/pubmed/33296054 http://dx.doi.org/10.1186/s40658-020-00339-2 |
_version_ | 1783620809716137984 |
---|---|
author | Sandström, Mattias Freedman, Nanette Fröss-Baron, Katarzyna Kahn, Tanweera Sundin, Anders |
author_facet | Sandström, Mattias Freedman, Nanette Fröss-Baron, Katarzyna Kahn, Tanweera Sundin, Anders |
author_sort | Sandström, Mattias |
collection | PubMed |
description | PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t(eff)) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points. METHODS: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after (177)Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t(eff) and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively. RESULTS: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t(eff) were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points. CONCLUSION: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit. |
format | Online Article Text |
id | pubmed-7726073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-77260732020-12-17 Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points Sandström, Mattias Freedman, Nanette Fröss-Baron, Katarzyna Kahn, Tanweera Sundin, Anders EJNMMI Phys Original Research PURPOSE: Fractionated peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t(eff)) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points. METHODS: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after (177)Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t(eff) and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively. RESULTS: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t(eff) were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points. CONCLUSION: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit. Springer International Publishing 2020-12-09 /pmc/articles/PMC7726073/ /pubmed/33296054 http://dx.doi.org/10.1186/s40658-020-00339-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Sandström, Mattias Freedman, Nanette Fröss-Baron, Katarzyna Kahn, Tanweera Sundin, Anders Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title | Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title_full | Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title_fullStr | Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title_full_unstemmed | Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title_short | Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points |
title_sort | kidney dosimetry in 777 patients during (177)lu-dotatate therapy: aspects on extrapolations and measurement time points |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726073/ https://www.ncbi.nlm.nih.gov/pubmed/33296054 http://dx.doi.org/10.1186/s40658-020-00339-2 |
work_keys_str_mv | AT sandstrommattias kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints AT freedmannanette kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints AT frossbaronkatarzyna kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints AT kahntanweera kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints AT sundinanders kidneydosimetryin777patientsduring177ludotatatetherapyaspectsonextrapolationsandmeasurementtimepoints |